Pfizer announced Friday evening that the Food and Drug Administration (FDA) has approved Cibinqo, a janus kinase (JAK) inhibitor, for the treatment of moderate to severe atopic dermatitis.
The biopharmaceutical group specifies that the green light from the American health authority concerns the use of this oral tablet in patients suffering from refractory forms of the disease, in whom existing therapies do not work.
Following this authorization, Cibinqo should be marketed on the American market in the next few weeks.
Post a Comment